Trial NCT05238831

View at ClinicalTrials.gov 
Org. Study IDs: STUDY00020679
Secondary IDs: NCI-2021-12938 STUDY00020679

Last trial update was posted on 2024-01-23

MeSH Interventions

Ado-Trastuzumab Emtansine Albumin-Bound Paclitaxel Alectinib Anastrozole Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Atezolizumab Bevacizumab Capecitabine Carboplatin Endothelial Growth Factors Entrectinib Fulvestrant Immunoconjugates Immunoglobulin G Immunoglobulins Irinotecan Letrozole Maytansine Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Phosphoinositide-3 Kinase Inhibitors Trastuzumab Trastuzumab biosimilar HLX02 Vemurafenib Vinorelbine

MeSH Conditions

Breast Neoplasms Carcinoma Carcinoma, Ovarian Epithelial Ovarian Neoplasms Pancreatic Neoplasms Prostatic Neoplasms Recurrence Sarcoma

Other Conditions

Advanced Breast Carcinoma Advanced Malignant Solid Neoplasm Advanced Ovarian Carcinoma Advanced Pancreatic Carcinoma Advanced Prostate Carcinoma Advanced Sarcoma Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Recurrent Adult Soft Tissue Sarcoma Recurrent Breast Carcinoma Recurrent Ovarian Carcinoma Recurrent Prostate Carcinoma Stage II Pancreatic Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8

Stopping Reasons

Withdrawn due to a change in therapeutic interventions.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID